NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Short Interest Up 63.0% in May

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) was the recipient of a large growth in short interest in May. As of May 15th, there was short interest totaling 45,302 shares, a growth of 63.0% from the April 30th total of 27,795 shares. Currently, 0.6% of the shares of the stock are sold short. Based on an average daily trading volume, of 37,277 shares, the short-interest ratio is presently 1.2 days.

NeuroOne Medical Technologies Stock Up 0.3%

NASDAQ:NMTC opened at $3.48 on Friday. NeuroOne Medical Technologies has a 12 month low of $3.27 and a 12 month high of $6.96. The firm has a market cap of $30.00 million, a price-to-earnings ratio of -4.09 and a beta of 0.51. The company’s 50 day moving average is $4.32 and its 200-day moving average is $4.48.

NeuroOne Medical Technologies (NASDAQ:NMTC) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). NeuroOne Medical Technologies had a negative net margin of 68.35% and a negative return on equity of 98.33%. The firm had revenue of $2.39 million during the quarter, compared to the consensus estimate of $2.58 million. Research analysts predict that NeuroOne Medical Technologies will post -0.35 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. JonesTrading started coverage on shares of NeuroOne Medical Technologies in a research report on Monday, March 2nd. They issued a “buy” rating and a $9.00 target price for the company. Wall Street Zen upgraded shares of NeuroOne Medical Technologies to a “sell” rating in a report on Saturday, February 21st. LADENBURG THALM/SH SH raised their target price on shares of NeuroOne Medical Technologies from $1.60 to $8.00 and gave the stock a “buy” rating in a report on Wednesday, May 13th. Weiss Ratings cut shares of NeuroOne Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, May 11th. Finally, Zacks Research cut shares of NeuroOne Medical Technologies from a “strong-buy” rating to a “hold” rating in a report on Friday, March 13th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, NeuroOne Medical Technologies currently has a consensus rating of “Hold” and a consensus price target of $11.67.

Institutional Investors Weigh In On NeuroOne Medical Technologies

A number of institutional investors have recently bought and sold shares of the business. Legato Capital Management LLC acquired a new stake in NeuroOne Medical Technologies during the fourth quarter worth $34,000. Squarepoint Ops LLC acquired a new stake in shares of NeuroOne Medical Technologies in the 4th quarter valued at $36,000. Susquehanna International Group LLP bought a new position in shares of NeuroOne Medical Technologies in the third quarter valued at about $47,000. XTX Topco Ltd raised its holdings in shares of NeuroOne Medical Technologies by 321.1% in the fourth quarter. XTX Topco Ltd now owns 85,454 shares of the company’s stock valued at $65,000 after buying an additional 65,163 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of NeuroOne Medical Technologies by 10.2% in the fourth quarter. Renaissance Technologies LLC now owns 763,028 shares of the company’s stock valued at $578,000 after buying an additional 70,428 shares during the last quarter. Institutional investors and hedge funds own 16.07% of the company’s stock.

NeuroOne Medical Technologies Company Profile

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.